The graduates and faculty of the University of Maryland School of Medicine (UMSOM) have made numerous important contributions to biology and medicine. These include the first selective coronary angiogram (F Mason Sones, MD'43), the differential responses to some blood pressure medications in African Americans (Elijah Saunders, MD'60), the demonstration of clinical effectiveness of implantable defibrillators to prevent sudden cardiac death (Michael Domanski, MD'77), the demonstration of beta-adrenergic receptor blockade to improve heart failure survival (Steve Gottlieb, MD), the role of calcium sparks in myocardial physiology (Jon Lederer, MD, PhD), the discovery of the first null mutation in APOC3 gene conferring cardioprotection by lowering triglyceride levels (Toni Pollin, PhD; Alan Shuldiner, MD, Michael Miller, MD), the first demonstration of a therapeutic approach for the iron-load-inflammatory axis for atherosclerosis (Aloke Finn, MD, Charles Hong, MD, PhD), and the first small molecule inhibitor of the bone morphogenetic protein (BMP) signaling (Charles Hong, MD, PhD).
The Cardiovascular Research Laboratories aim to continue this proud tradition of discovery and innovation by leveraging the unique resources of UMSOM and bringing together an interdisciplinary team of basic and clinical investigators to advance human cardiovascular biology, to train future leaders of cardiovascular medicine, and to transform the practice of clinical cardiology.
To provide premier cardiovascular care through a focus on quality and efficiency of patient care, groundbreaking research, and inspired education.
Together, these three pillars of cardiovascular medicine support our efforts to devise unique treatment plans for each patient using innovative surgical and minimally invasive techniques as well as cutting-edge medicine.